

SERVICIO ANDALUZ DE SALUD

DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS


C. MONTERO-VILCHEZ¹, M.P. AZNARTE-PADIAL¹, A. ESPINOSA-RODRIGUEZ¹, <u>M.R. CANTUDO CUENCA¹</u>. ¹VIRGEN DE LAS NIEVES UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, GRANADA, SPAIN.


BACKGROUND AND IMPORTANCE:

Dalbavancin is a semisynthetic glycopeptide active against Gram positive bacteria, approved in bacterial skin and skin structure infections(ABSSSI). Its use has been extended, in selected patients, to other complicated infections to avoid prolonging the hospital stay, such as: endocarditis, bacteremia with difficulty controlling focus, and osteoarticular infections. The usual treatment regimen is a loading dose of 1500mg followed by 1000mg after fifteen days.

AIM AND OBJECTIVES

The objective of the study was to evaluate the days of hospital stay avoided with the use of Dalbavancin in these patients.





	Osteoarticular infections		An average of 30 days		
	Endocarditis	61.5% (8 patients)	30 days avoided		citis
		23.1% (3 patients)	15 days avoided	Septic prosthetic infections Osteoarticular infections spondylodiscitis	

CONCLUSION AND RELEVANCE

The use of Dalbavancin in selected patients, in infections that require prolonged hospital stay due to receive intravenous treatment, has been shown to be useful in shortening the length of hospital stay.



Abstract: 5PSQ-091 Historical research

26th Congress – Hospital Pharmacists – changing roles in a changing world